Chemoprevention of BBN-induced bladder carcinogenesis by the selective Estrogen receptor modulator tamoxifen

Translational Oncology

Volumn 6, Issue 3, 2013, Pages 244-255

  George, Suraj Konnath ^a   Tovar Sepulveda, Veronica ^a   Shen, Steven S ^b   Jian, Weiguo ^a   Zhang, Yiqun ^a   Hilsenbeck, Susan G ^a   Lerner, Seth P ^a   Smith, Carolyn L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; KI 67 ANTIGEN; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER INCIDENCE; CARCINOGENESIS; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR GROWTH;

EID: 84878732666     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13247     Document Type: Article

References (87)

1. Siegel R, Naishadham D, and Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin 62, 10-29.
2. Heney NM (1992). Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am 19, 429-433.
3. McGrath M, Michaud DS, and De Vivo I (2006). Hormonal and reproductive factors and the risk of bladder cancer in women. Am J Epidemiol 163, 236-244.
4. Imada S, Akaza H, Ami Y, Koiso K, Ideyama Y, and Takenaka T (1997). Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. Eur Urol 31, 360-364.
5. Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang Y-J, Hu Y-C, Tsai M-Y, et al. (2007). Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 99, 558-568.
6. Noronha RFX and Rao BR (1986). Sex hormone receptors in localized and advanced transitional cell carcinoma of urinary tract in humans. Urology 28, 401-403.
7. Laor E, Schiffman ZJ, Braunstein JD, Tolia BM, Koss LG, and Freed SZ (1985). Androgen receptors in bladder tumors. Urology 25, 161-163.
8. Tuygun C, Kankaya D, Imamoglu A, Sertcelik A, Zengin K, Oktay M, and Sertcelik N (2011). Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol 29, 43-51.
9. Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu I, Izumi K, Chang C, Messing EM, Netto GJ, and Yeh S (2012). Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int 109, 1716-1726.
10. Cantor KP, Lynch CF, and Johnson D (1992). Bladder cancer, parity, and age at first birth. Cancer Causes Control 3, 57-62.
11. Miller AB, Barclay TH, Choi NW, Grace MG, Wall C, Plante M, Howe GR, Cinader B, and Davis FG (1980). A study of cancer, parity and age at first pregnancy. J Chronic Dis 33, 595-605.
12. Davis-Dao CA, Henderson KD, Sullivan-Halley J, Ma H, West D, Xiang Y-B, Gago-Dominguez M, Stern MC, Castelao JE, Conti DV, et al. (2011). Lower risk in parous women suggests that hormonal factors are important in bladder cancer etiology. Cancer Epidemiol Biomarkers Prev 20, 1156-1170.
13. Dietrich K, Demidenko E, Schned A, Zens MS, Heaney J, and Karagas MR (2011). Parity, early menopause and the incidence of bladder cancer in women: a case-control study and meta-analysis. Eur J Cancer 47, 592-599.
14. Wolpert BJ, Amr S, Ezzat S, Saleh D, Gouda I, Loay I, Hifnawy T, Mikhail NN, Abdel-Hamid M, Zhan M, et al. (2010). Estrogen exposure and bladder cancer risk in Egyptian women. Maturitas 67, 353-357.
15. Shirai T, Tsuda H, Ogiso T, Hirose M, and Ito N (1987). Organ specific modifying potential of ethinyl estradiol on carcinogenesis initiated with different carcinogens. Carcinogenesis 8, 115-119.
16. Okajima E, Hiramatsu T, Iriya K, Ijuin M, Matsushima S, and Yamada K (1975). Effects of sex hormones on development of urinary bladder tumours in rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Urol Res 3, 73-79.
17. Johnson AM, O'Connell MJ, Messing EM, and Reeder JE (2008). Decreased bladder cancer growth in parous mice. Urology 72, 470-473.
18. Wolf H, Wandt H, and Jonat W (1991). Immunohistochemical evidence of estrogen and progesterone receptors in the female lower urinary tract and comparison with the vagina. Gynecol Obstet Invest 32, 227-231.
19. Pacchioni D, Revelli A, Casetta G, Cassoni P, Piana P, Tizzani A, Bussolati G, and Massobrio M (1992). Immunohistochemical detection of estrogen and progesterone receptors in the normal urinary bladder and in pseudomembranous trigonitis. J Endocrinol Invest 15, 719-725.
20. Miyamoto H, Zheng Y, and Izumi K (2012). Nuclear hormone receptor signals as new therapeutic targets for urothelial carcinoma. Curr Cancer Drug Targets 12, 14-22.
21. Tincello DG, Taylor AH, Spurling SM, and Bell SC (2009). Receptor isoforms that mediate estrogen and progestagen action in the female lower urinary tract. J Urol 181, 1474-1482.
22. Kontos S, Kominea A, Melachrinou M, Balampani E, and Sotiropoulou-Bonikou G (2010). Inverse expression of estrogen receptor-β and nuclear factor-κB in urinary bladder carcinogenesis. Int J Urol 17, 801-809.
23. Taylor AH and Al-Azzawi F (2000). Immunolocalisation of oestrogen receptor beta in human tissues. J Mol Endocrinol 24, 145-155.
24. Pearse G, Frith J, Randall KJ, and Klinowska T (2009). Urinary retention and cystitis associated with subcutaneous estradiol pellets in female nude mice. Toxicol Pathol 37, 227-234.
25. Rosenzweig BA, Bolina PS, Birch L, Moran C, Marcovici I, and Prins GS (1995). Location and concentration of estrogen, progesterone, and androgen receptors in the bladder and urethra of the rabbit. Neurourol Urodyn 14, 87-96.
26. Saunders PTK, Maguire SM, Gaughan J, and Millar MR (1997). Expression of oestrogen receptor beta (ERβ) in multiple rat tissues visualized by immunohistochemistry. J Endocrinol 154, R13-R16.
27. Mäkelä S, Strauss L, Kuiper G, Valve E, Salmi S, Santti R, and Gustafsson J-Å (1985). Differential expression of estrogen receptors alpha and beta in adult rat accessory sex glands and lower urinary tract. Mol Cell Endocrinol 170, 219-229.
28. Salmi S, Santti R, Gustafsson J-Å, and Mäkelä S (2001). Co-localization of androgen receptor with estrogen receptor β in the lower urinary tract of the male rat. J Urol 166, 674-677.
29. Rosenfeld CS, Ganjam VK, Taylor JA, Yuan X, Stiehr JR, Hardy MP, and Lubahn DB (1998). Transcription and translation of estrogen receptor-β in the male reproductive tract of estrogen receptor-α knock-out and wild-type mice. Endocrinology 139, 2982-2987.
30. Pelletier G (2000). Localization of androgen and estrogen receptors in rat and primate tissues. Histol Histopathol 15, 1261-1270.
31. Imamov O, Yakimchuk K, Morani A, Schwend T, Wada-Hiraike O, Razumov S, Warner M, and Gustafsson J-Å (2007). Estrogen receptor β-deficient female mice develop a bladder phenotype resembling human interstitial cystitis. Proc Natl Acad Sci USA 104, 9806-9809.
32. Kaufmann O, Baume H, and Dietel M (1998). Detection of oestrogen receptors in non-invasive and invasive transitional cell carcinomas of the urinary bladder using both conventional immunohistochemistry and the tyramide staining amplification (TSA) technique. J Pathol 186, 165-168.
33. Basakci A, Kirkali Z, Tuzel E, Yorukoglu K, Mungan MU, and Sade M (2002). Prognostic significance of estrogen receptor expression in superficial transitional cell carcinoma of the urinary bladder. Eur Urol 41, 342-345.
34. Croft PR, Lathrop SL, Feddersen RM, and Joste NE (2005). Estrogen receptor expression in papillary urothelial carcinoma of the bladder and ovarian transitional cell carcinoma. Arch Pathol Lab Med 129, 194-199.
35. Shen SS, Smith CL, Hsieh JT, Yu J, Kim IY, Jian W, Sonpavde G, Ayala GE, Younes M, and Lerner SP (2006). Expression of estrogen receptors-α and-β in bladder cancer cell lines and human bladder tumor tissue. Cancer 106, 2610-2616.
36. Bolenz C, Lotan Y, Ashfaq R, and Shariat SF (2009). Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder. Eur Urol 56, 1093-1095.
37. Bødker A, Balslev E, Juul BR, Stimpel H, Meyhoff HH, Hedlund H, Hedlund P, Iversen HG, and Andersson KE (1995). Estrogen receptors in the human male bladder, prostatic urethra, and prostate. An immunohistochemical and biochemical study. Scand J Urol Nephrol 29, 161-165.
38. Wei S, Said-Al-Naief N, and Hameed O (2009). Estrogen and progesterone receptor expression is not always specific for mammary and gynecologic carcinomas: a tissue microarray and pooled literature review study. Appl Immunohistochem Mol Morphol 17, 393-402.
39. Kontos S, Papatsoris A, Kominea A, Melachrinou M, Tanoglidi A, Kachrilas S, Karavitakis M, Balampani E, and Sotiropoulou-Bonikou G (2011). Expression of ERβ and its co-regulators p300 and NCoR in human transitional cell bladder cancer. Urol Int 87, 151-158.
40. Han B, Cui D, Jing Y, Hong Y, and Xia S (2012). Estrogen receptor β (ERβ) is a novel prognostic marker of recurrence survival in non-muscle-invasive bladder cancer potentially by inhibiting cadherin switch. World J Urol 30, 861-867.
41. Thomas C and Gustafsson J-Å (2011). The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 11, 597-608.
42. Teng J, Wang Z-Y, Jarrard DF, and Bjorling DE (2008). Roles of estrogen receptor α and β in modulating urothelial cell proliferation. Endocr Relat Cancer 15, 351-364.
43. Hoffman KL, Lerner SP, and Smith CL (2013). Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation. Horm Cancer 4, 24-35.
44. Sonpavde G, Okuno N, Weiss H, Yu J, Shen SS, Younes M, Jian W, Lerner SP, and Smith CL (2007). Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma. Urology 69, 1221-1226.
45. Kim HT, Kim BC, Kim IY, Mamura M, Seong do H, Jang JJ, and Kim SJ (2002). Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis through cleavage of BAD in TSU-PR1 human cancer cells. J Biol Chem 277, 32510-32515.
46. Ito N, Fukushima S, Shirai T, Nakanishi K, Hasegawa R, and Imaida K (1983). Modifying factors in urinary bladder carcinogenesis. Environ Health Perspect 49, 217-222.
47. Fukushima S, Hirose M, Tsuda H, Shirai T, and Hirao K (1976). Histological classification of urinary bladder cancers in rats induced by N-butyl-n-(4-hydroxybutyl)nitrosamine. Gann 67, 81-90.
48. Kunze E, Schauer A, and Krüsmann G (1975). Focal loss of alkaline phosphatase and increase of proliferation in preneoplastic areas of the rat urothelium after administration of n-butyl-n-(4-hydroxybutyl)-nitrosamine and n-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 84, 143-160.
49. Williams PD, Lee JK, and Theodorescu D (2008). Molecular credentialing of rodent bladder carcinogenesis models. Neoplasia 10, 838-846.
50. Bertram JS and Craig AW (1972). Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response. Eur J Cancer 8, 587-594.
51. Gavrieli Y, Sherman Y, and Ben-Sasson SA (1992). Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119, 493-501.
52. Spano JP, Lagorce C, Atlan D, Milano G, Dormont J, Benamouzig R, Attar A, Benichou J, Martin A, Morere JF, et al. (2005). Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 16, 102-108.
53. Becci PJ, Thompson HJ, Grubbs CJ, Squire RA, Brown CC, Sporn MB, and Moon RC (1978). Inhibitory effect of 13-cis-retinoic acid on urinary bladder carcinogenesis induced in C57BL/6 mice by N-butyl-N-(4-hydroxybutyl)-nitrosamine. Cancer Res 38, 4463-4466.
54. McCormick DL, Ronan SS, Becci PJ, and Moon RC (1981). Influence of total dose and dose schedule on induction of urinary bladder cancer in the mouse by N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis 2, 251-254.
55. Tyagi A, Raina K, Singh RP, Gu M, Agarwal C, Harrison G, Glode LM, and Agarwal R (2007). Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder carcinogenesis in male ICR mice. Mol Cancer Ther 6, 3248-3255.
56. Yao R, Lemon WJ, Wang Y, Grubbs CJ, Lubet RA, and You M (2004). Altered gene expression profile in mouse bladder cancers induced by hydroxybutyl(butyl) nitrosamine. Neoplasia 6, 569-577.
57. Yao R, Yi Y, Grubbs CJ, Lubet RA, and You M (2007). Gene expression profiling of chemically induced rat bladder tumors. Neoplasia 9, 207-221.
58. Koskela S, Lehtonen S, Santala M, Venhola M, Parpala-Spårman T, and Lehenkari P (2009). 17β-Estradiol induces the proliferation of the in vitro cultured human urothelium. Scand J Urol Nephrol 43, 179-185.
59. Lin W, Rahman NA, Lin J, Zhang H, Gou K, Yu W, Zhu D, Li N, Huhtaniemi I, and Li X (2011). Molecular mechanisms of bladder outlet obstruction in transgenic male mice overexpressing aromatase (Cyp19a1). Am J Pathol 178, 1233-1244.
60. Abdelrahim M, Samudio I, Smith R III, Burghardt R, and Safe S (2002). Small inhibitory RNA duplexes for Sp1 mRNA block basal and estrogen-induced gene expression and cell cycle progression in MCF-7 breast cancer cells. J Biol Chem 277, 28815-28822.
61. Blakeman PJ, Hilton P, and Bulmer JN (2001). Cellular proliferation in the female lower urinary tract with reference to oestrogen status. BJOG 108, 813-816.
62. Wang D, Hu L, Zhang G, Zhang L, and Chen C (2010). G protein-coupled receptor 30 in tumor development. Endocrine 38, 29-37.
63. Kim SK, Yun SJ, Kim J, Lee OJ, Bae SC, and Kim WJ (2011). Identification of gene expression signature modulated by nicotinamide in a mouse bladder cancer model. PLoS One 6, e26131.
64. Waalkes MP, Liu J, Ward JM, Powell DA, and Diwan BA (2006). Urogenital carcinogenesis in female CD1 mice induced by in utero arsenic exposure is exacerbated by postnatal diethylstilbestrol treatment. Cancer Res 66, 1337-1345.
65. Bødker A, Andersson K-E, Batra S, Juhl BR, and Meyhoff H-H (1994). The estrogen receptor expression in the male rabbit urethra and prostate following castration. Scand J Urol Nephrol 28, 113-118.
66. Klinge CM (2012). miRNAs and estrogen action. Trends Endocrinol Metab 23, 223-233.
67. Zhao Y, Deng C, Wang J, Xiao J, Gatalica Z, Recker RR, and Xiao GG (2011). Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer. Breast Cancer Res Treat 127, 69-80.
68. Lu Y, Liu P, Van den Bergh F, Zellmer V, James M, Wen W, Grubbs CJ, Lubet RA, and You M (2011). Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer. Cancer Prev Res (Phila) 5, 248-259.
69. Duong V, Boulle N, Daujat S, Chauvet J, Bonnet S, Neel H, and Cavaillès V (2007). Differential regulation of estrogen receptor α turnover and transactivation by Mdm2 and stress-inducing agents. Cancer Res 67, 5513-5521.
70. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, and Gustafsson J-A (2004). Estrogen receptor β inhibits 17β-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 101, 1566-1571.
71. Paruthiyil S, Cvoro A, Tagliaferri M, Cohen I, Shtivelman E, and Leitman DC (2011). Estrogen receptor β causes a G2 cell cycle arrest by inhibiting CDK1 activity through the regulation of cyclin B1, GADD45A, and BTG2. Breast Cancer Res Treat 129, 777-784.
72. Edvardsson K, Ström A, Jonsson P, Gustafsson J-Å, and Williams C (2011). Estrogen receptor β induces antiinflammatory and antitumorigenic networks in colon cancer cells. Mol Endocrinol 25, 969-979.
73. Weihua Z, Saji S, Mäkinen S, Cheng G, Jensen EV, Warner M, and Gustafsson J-Å (2000). Estrogen receptor (ER) β, a modulator of ERα in the uterus. Proc Natl Acad Sci USA 97, 5936-5941.
74. Monroe DG, Getz BJ, Johnsen SA, Riggs BL, Khosla S, and Spelsberg TC (2003). Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERα or ERβ. J Cell Biochem 90, 315-326.
75. Matthews J, Wihlén B, Tujague M, Ström A, and Gustafsson J-Å (2006). Estrogen receptor (ER) β modulates ERα-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Mol Endocrinol 20, 534-543.
76. Chang EC, Frasor J, Komm B, and Katzenellenbogen BS (2006). Impact of estrogen receptor β on gene networks regulated by estrogen receptor α in breast cancer cells. Endocrinology 147, 4831-4842.
77. Thomas C, Rajapaksa G, Nikolos F, Hao R, Katchy A, McCollum CW, Bondesson M, Quinlan P, Thompson A, Krishnamurthy S, et al. (2012). ERβ1 represses basal-like breast cancer epithelial to mesenchymal transition by destabilizing EGFR. Breast Cancer Res 14, R148.
78. Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti CA, Gouvin LM, Sharma VM, and Mercurio AM (2010). ERβ impedes prostate cancer EMT by destabilizing HIF-1α and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 17, 319-332.
79. Airoldi L, Magagnotti C, Bonfanti M, and Fanelli R (1990). Alpha-oxidative metabolism of the bladder carcinogens N-nitrosobutyl(4-hydroxybutyl)amine and N-nitrosobutyl(3-carboxypropyl)amine within the rat isolated bladder. Carcinogenesis 11, 1437-1440.
80. Hashimoto Y and Kitagawa HS (1974). In vitro neoplastic transformation of epithelial cells of rat urinary bladder by nitrosamines. Nature 252, 497-499.
81. Bonfanti M, Magagnotti C, Bonati M, Fanelli R, and Airoldi L (1988). Pharmacokinetic profile and metabolism of N-nitrosobutyl-(4-hydroxybutyl)amine in rats. Cancer Res 48, 3666-3669.
82. Izumi K, Li Y, Ishiguro H, Zheng Y, Yao JL, Netto GJ, and Miyamoto H (2013). Expression of UDP-glucuronosyltransferase 1A in bladder cancer: association with prognosis and regulation by estrogen. Mol Carcinog 52, 94-102.
83. Gelmann EP (1997). Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin Oncol 24, S1-65-S1-70.
84. Pu Y-S, Hsieh T-S, Tsai T-C, Cheng A-L, Hsieh C-Y, Su I-J, and Lai M-K (1995). Tamoxifen enhances the chemosensitivity of bladder carcinoma cells. J Urol 154, 601-605.
85. Pu YS, Hsieh TS, Cheng AL, Tseng NF, Su IJ, Hsieh CY, Lai MK, and Tsai TC (1996). Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: a potential use in intravesical chemotherapy. Br J Urol 77, 76-85.
86. Hsu CH, Chen J, Wu CY, Cheng AL, and Pu YS (2001). Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma. Anticancer Res 21, 711-715.
87. Dellagrammaticas D, Bryden AA, and Collins GN (2001). Regression of metastatic transitional cell carcinoma in response to tamoxifen. J Urol 165, 1631.